The oral selective JAK kinase inhibitor, Upadacitinib (UPA; Rinvoq) has been shown to induce and maintain clinical response and remission in Crohn's disease (CD), but also in rheumatic and skin diseases. We report here on the largest Swiss experience in "off label" use of this drug. ...
Regulated in response to drug exposure Can be used as markers of drug responses [20] Regulate the expression of inflammatory cytokines Potential therapeutic targets in IBD [21,22,23] Act on the intestinal barrier Potential therapeutic targets in IBD [25,26] Modulate the intestinal microbiota Potent...
Crohn’s disease is one of the major subtypes of idiopathic inflammatory bowel disease and is characterized by chronic transmural intestinal inflammation of the gastrointestinal tract anywhere from mouth to the anus, with a predilection for the small bowel. Cross-sectional imaging with computed tomograph...
Ustekinumab and vedolizumab exposure during pregnancy and lactation are both considered low risk by the recent ECCO guidelines despite the limited data that are currently available. Keywords: therapeutic drug monitoring; pregnancy; breastfeeding; inflammatory bowel disease...